We are the combination of four hospitals: the General Hospital, the Children’s Hospital, the Women’s Hospital and the Traumatology, Rehabilitation and Burns Hospital. We are part of the Vall d’Hebron Barcelona Hospital Campus: a world-leading health park where healthcare plays a crucial role.
Patients are the centre and the core of our system. We are professionals committed to quality care and our organizational structure breaks down the traditional boundaries between departments and professional groups, with an exclusive model of knowledge areas.
Would you like to know what your stay at Vall d'Hebron will be like? Here you will find all the information.
The commitment of Vall d'Hebron University Hospital to innovation allows us to be at the forefront of medicine, providing first class care adapted to the changing needs of each patient.
Most high-risk neuroblastoma respond to therapy by complete clinical remission, but frequently relapse as therapy-resistant disease. Our lab aims to elucidate this enigmatic process and to devise new treatment options to prevent resistance and relapse.
We have identified that neuroblastoma includes lineage-committed adrenergic (ADRN) cells and a minor fraction of undifferentiated mesenchymal (MES) tumor cells. These cell states can spontaneously transdifferentiate and have been extensively characterized for their transcriptional states, chromatin landscapes and lineage transcription factor networks. Importantly, MES cells are resistant to a wide variety of drugs used in the clinical management of neuroblastoma. We have developed an in vivo relapse model and found that combinations of MES- and ADRN-specific drugs delays the onset of relapses. I will discuss how normal development and tumour cell heterogeneity provide a framework to understand resistance and the potential for relapse development.
Short CV: Johan van Nes studied Biology and obtained a PhD from Utrecht University for his work on mouse developmental genetics. He leads a research group that studies the biology of relapse development in the childhood tumour neuroblastoma (Amsterdam UMC, location AMC, Amsterdam). His research focuses on fundamental insights in intra-tumour heterogeneity and tumour cell plasticity to identify new therapeutic combinations to combat relapses.
Host: Miguel Segura / Carlos Jiménez, Group of Translational Research in Child and Adolescent Cancer. Vall d'Hebron Institut of Research (VHIR). Hospital Universitari Vall d'Hebron
Format: Face-to-face and online Streaming link: click here
LLoc: Sala d'Actes de la planta baixa de l'HG
The acceptance of these terms implies that you give your consent to the processing of your personal data for the provision of the services you request through this portal and, if applicable, to carry out the necessary procedures with the administrations or public entities involved in the processing. You may exercise the mentioned rights by writing to web@vallhebron.cat, clearly indicating in the subject line “Exercise of LOPD rights”. Responsible entity: Vall d’Hebron University Hospital (Catalan Institute of Health). Purpose: Subscription to the Vall d’Hebron Barcelona Hospital Campus newsletter, where you will receive news, activities, and relevant information. Legal basis: Consent of the data subject. Data sharing: If applicable, with VHIR. No other data transfers are foreseen. No international transfer of personal data is foreseen. Rights: Access, rectification, deletion, and data portability, as well as restriction and objection to its processing. The user may revoke their consent at any time. Source: The data subject. Additional information: Additional information can be found at https://hospital.vallhebron.com/es/politica-de-proteccion-de-datos.